Navigation Links
New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
Date:5/1/2008

SEATTLE, May 1 /PRNewswire/ -- Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results, especially if a major tumor suppressor gene -- p53 -- is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.

IGF-1 is a polypeptide hormone that can influence growth, differentiation and survival of cells expressing the type 1 receptor (IGF-1R). Past clinical, epidemiological and experimental studies have strongly implicated IGF-1 as a contributing factor in the natural history of prostate cancer. However, very little has been done to prove absolutely that the expression or activation of the IGF-1 signaling pathway at physiologically relevant levels is sufficient to cause a healthy prostate cell to become a cancer cell.

Norman Greenberg, Ph.D., and colleagues conducted a pair of experiments by manipulating gene expression directly in the epithelial compartment of the mouse prostate gland to better understand the role of IGF-1R. In contrast to studies that correlated elevated levels of IGF-1 with the risk of developing prostate cancer, Greenberg's research showed that eliminating IGF-1R expression in an otherwise normal mouse prostate caused the cells to proliferate and become hyperplastic. Although persistent loss of IGF-1R expression ultimately induced cell stasis and death, both of these processes are regulated by the tumor suppressor gene p53 that is commonly mutated in human prostate cancers. Hence the researchers hypothesized that tumors with compromised p53 might not respond predictably to therapies targeting IGF1 signaling.

To test their reasoning they conducted a second experiment by crossing mice carrying the prostate-specific IGF-1R knockout alleles with transgenic mice that develop spontaneous prostate cancer when p53 and select other genes are compromised. The resul
'/>"/>

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Statement from Lighthouse International About the Study on Gene Therapy Concerning Lebers Congenital Amaurosis
2. Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood
3. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
4. Dosing for RVX-208 Phase 1a Clinical Study Completed
5. Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease
6. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
7. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
8. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
9. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)...  Together with its customers, Elekta raised EUR 30,575 ... Barcelona . The funds will be donated ... to improve cancer care, specifically radiation oncology care, around ... patient should be denied potentially life-saving treatment simply because ... hospitals and clinics around the world to take care ...
(Date:4/25/2015)... Join us for a webinar at ... Residence Times using the Transcreener® ADP Assay , ... is increasingly being incorporated into lead development efforts because ... efficacy, increased therapeutic window and reduced side effects. ... methods such surface plasmon resonance, conjugation of drugs can ...
(Date:4/24/2015)... and Tempe, AZ (PRWEB) April 24, 2015 ... and Arizona State University (ASU) have entered into an ... projects. , A memorandum of agreement signed by the ... distance learning, student success and other services particularly, though ... , “We have complementary strengths and a similar ...
(Date:4/24/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... National Restaurant Association’s NRA Show 2015, in Chicago, ... the company will be available to share information ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 2South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2DryLet to Showcase Bio-React at the National Restaurant Association’s NRA Show 2015 May 16-19, 2015 in Chicago, Illinois 2
... - First publication on utility of PRDT,s prion reduction technology to, ... ... Octaplas(R), - Octapharma ... removal capacity, technical performance and product quality., MONTREAL, ...
... Printed electronics holds possibilities for applications including printed organic solar ... ... flexible displays, ST. LOUIS, June 10 Sigma-Aldrich (Nasdaq:,SIAL) announced ... leading innovator of technology for printed,electronics, to distribute its organic semiconductors ...
... N.J., June 9 Davie Floyd, Director ... Peer Group, an Informed Medical,Communications company, were ... Trainers 37th Annual Conference in Orlando, FL. ... influential dialogue, Floyd and Bresette,presented the topic ...
Cached Biology Technology:ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials 2Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials 3Experts From The Peer Group Provide Training on Dialogue-Based Influence at the SPBT Annual Conference 2
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... reverse the symptoms of a rare form of muscular ... medical geneticists at Duke University Medical Center. Infants born ... die before they reach the age of two. The ... to muscles may have application in treating other muscular ...
... a new bacteria that is a natural cleanser for ... world, is an inexpensive and highly effective solution to ... be a master engineer,?said Ron Sims, biological and irrigation ... have put these carcinogens in our environment, and nature ...
... the flow of water molecules through the brain can help ... if a patient's tumor will shrink, a new study shows. ... developed the assessment, which they call a functional diffusion map. ... diffusion, or movement, of water through the brain and mapped ...
Cached Biology News:Muscle-targeted gene therapy reverses rare muscular dystrophy in mice 2Muscle-targeted gene therapy reverses rare muscular dystrophy in mice 3Solution to Pollution: New Bacteria Eats Toxic Waste 2Solution to Pollution: New Bacteria Eats Toxic Waste 3New imaging method gives early indication if brain cancer therapy is effective, U-M study shows 2New imaging method gives early indication if brain cancer therapy is effective, U-M study shows 3
Acid phosphatase (Potato). Monospecific by IEP. Some cross reactivity between Acid phosphatases of other species may occur....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Biology Products: